# 18F-Floretyrosine Expanded Access Program

> **NCT06743100** · — · AVAILABLE · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited**

## Conditions studied

- Glioma (Any Grade) in the Brain

## Interventions

- **DIAGNOSTIC_TEST:** 18F-Floretyrosine

## Key facts

- **NCT ID:** NCT06743100
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06743100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06743100, "18F-Floretyrosine Expanded Access Program". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06743100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*